inhA , a Gene Encoding a Target for Isoniazid and Ethionamide in Mycobacterium tuberculosis
The DOI matches its Crossref record; 44 of the 46 references it cites were found in a registry or an index.
Abstract
Isoniazid (isonicotinic acid hydrazide, INH) is one of the most widely used antituberculosis drugs, yet its precise target of action on Mycobacterium tuberculosis is unknown. A missense mutation within the mycobacterial inhA gene was shown to confer resistance to both INH and ethionamide (ETH) in M. smegmatis and in M. bovis . The wild-type inhA gene also conferred INH and ETH resistance when transferred on a multicopy plasmid vector to M. smegmatis and M. bovis BCG. The InhA protein shows significant sequence conservation with the Escherichia coli enzyme EnvM, and cell-free assays indicate that it may be involved in mycolic acid biosynthesis. These results suggest that InhA is likely a primary target of action for INH and ETH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“inhA was identified as the target of activated INH by an M. smegmatis missense mutation that conferred co-resistance to both INH and Ethionamide (ETH) (129).”
From Mycobacterium smegmatis: The Vanguard of Mycobacterial Research (2023) · cites this paper as [129]
Citations
Cites
Introduction to Protein Structure
Branden, C. I., & Tooze, J. (2012) · Garland Science eBooks · doi:10.1201/9781136969898 · Cited by 2,382
Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis
Telenti, A., Imboden, P., Marchesi, F., Matter, L., Schopfer, K., Bodmer, T., Lowrie, D., Colston, M. J., & Cole, S. (1993) · The Lancet · doi:10.1016/0140-6736(93)90417-f · Cited by 1,337
The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis
Zhang, Y., Heym, B., Allen, B., Young, D., & Cole, S. (1992) · Nature · doi:10.1038/358591a0 · Cited by 1,299
Snapper, S. B., Melton, R. E., Mustafa, S., Kieser, T., & Jr, W. R. J. (1990) · Molecular Microbiology · doi:10.1111/j.1365-2958.1990.tb02040.x · Cited by 1,237
Self-citationThe Emergence of Drug-Resistant Tuberculosis in New York City
Frieden, T. R., Sterling, T., Pablos-Mendez, A., Kilburn, J. O., Cauthen, G. M., & Dooley, S. W. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302253280801 · Cited by 939
Tuberculosis in developing countries: burden, intervention and cost.
Murray, C. J. L., Styblo, K., & Rouillon, A. (1990) · PubMed · Cited by 571
[25] Genetic systems for mycobacteria
Jacobs, W. R., Kalpana, G. V., Cirillo, J. D., Pascopella, L., Snapper, S. B., Udani, R. A., Jones, W., Barletta, R. G., & Bloom, B. R. (1991) · Methods in Enzymology · doi:10.1016/0076-6879(91)04027-l · Cited by 433
Self-citationSnider, D. E., & Roper, W. L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203053261011 · Cited by 382
Combs, D. L., O'Brien, R. J., & Geiter, L. J. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-3-112-6-397 · Cited by 315
Takayama, K., Wang, L., & David, H. L. (1972) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.2.1.29 · Cited by 292
Research works printed but not linked: 8
- BEGGS, W.H., AM REV RESPIR DIS 102: 94 (1969).
- GOPINATHAN, K.P., SPECIFICITY OF ISONIAZID ACTION AGAINST MYCOBACTERIA AND A POSSIBLE MECHANISM FOR THE DEVELOPMENT OF DRUG-RESISTANCE, CURRENT SCIENCE 50: 216 (1981).
- GRUMBACH, F, REVUE DE TUBERCULOSE ET DE PNEUMOLOGIE 25: 1365 (1961).
- MIDDLEBROOK, G, AMERICAN REVIEW OF TUBERCULOSIS 65: 765 (1952).
- MURRAY, C. J. L., BULLETIN OF THE INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE 65: 6 (1990).
- Murray, C., Disease Control Priorities in Developing Countries: 233 (1993).
- OFFE, H.A., ZEITSCHRIFT FUR NATURFORSCHUNG 76: 462 (1952).
- PANSY, F, INVITRO STUDIES ON ISONICOTINIC ACID HYDRAZIDE, AMERICAN REVIEW OF TUBERCULOSIS 65: 761 (1952).
Cited by
Items 801–900 of 1,000
Murray, J. L., Hu, P., & Shafer, D. A. (2014) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.06.008 · Cited by 17
“Figure 7, BeD show applications of G-Force probes as low-cost reference probes for detecting an SNP in the human VKORC1 gene (rs9923231) related to 635 warfarin dosing24 and the major mutant site of inhA that confers isoniazid drug resistance in MTB.25 The G-Force probe labels the amplicon one color (eg, FAM) irrespec…”
BackgroundKumar, V., & Sobhia, M. E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144635 · Cited by 17
Fármacos con actividad frente a Mycobacterium tuberculosis
Coll, P. (2003) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(03)72945-0 · Cited by 50
Martinelli, L. K. B., Rotta, M., Villela, A. D., Rodrigues-Junior, V. S., Abbadi, B. L., Trindade, R. V., Petersen, G. O., Danesi, G. M., Nery, L. R., Pauli, I., et al. (2017) · Scientific Reports · doi:10.1038/srep46696 · Cited by 19
Guo, J.-H., Xiang, W., Zhao, Q., Luo, T., Huang, M. Z., Zhang, J., Zhao, J., Yang, Z., & Sun, Q. (2008) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.jjid.2008.264 · Cited by 18
“The upriver regulatory region of the enoyl acyl carrier protein reductase gene (inhA) is also associated with the INH resistance of M. tuberculosis ( 8 ,9).”
BackgroundIsoniazid Induces Its Own Resistance in Nonreplicating Mycobacterium tuberculosis
Siddiqi, S. H., Takhar, P., Baldeviano, C., Glover, W. A., & Zhang, Y. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00086-07 · Cited by 19
“Mutations in the inhA encoding the drug target or mutations in its promoter can cause INH resistance (1).”
BackgroundAlcaraz, M., Edwards, T. E., & Kremer, L. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2224563 · Cited by 19
Cho, E., Bae, H. K., Kang, S. K., & Lee, E. H. (2009) · Annals of Laboratory Medicine · doi:10.3343/kjlm.2009.29.5.455 · Cited by 16
“Mutations in the inhAgene are also known to confer resistance to ethionamide (ETH); therefore, the ETH susceptibility of the INH-resistant strains was examined in this study [18].”
BackgroundKamsri, P., Koohatammakun, N., Srisupan, A., Meewong, P., Punkvang, A., Saparpakorn, P., Hannongbua, S., Wolschann, P., Prueksaaroon, S., Leartsakulpanich, U., et al. (2014) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2014.898690 · Cited by 16
Li, G., Zhang, J., Jiang, Y., Zhao, L., Liu, H., Li, M., Zhao, X., & Wan, K. (2019) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2019.08.005 · Cited by 16
Usha, V., Dover, L. G., Roper, D. I., & Besra, G. S. (2008) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2007.01049.x · Cited by 16
“Historically, the biosynthesis of the mycobacterial cell wall has provided a useful chemotherapeutic target with component enzymes inhibited by isoniazid, ethionamide and ethambutol (Takayama & Kilburn, 1989; Banerjee et al., 1994; Kremer et al., 2003; Vilcheze et al., 2006).”
BackgroundMechanisms of resistance to xenobiotics in human therapy
Saves, I., & Masson, J. (1998) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050170 · Cited by 18
Vale, N., Correia, A., Silva, S., Figueiredo, P., Mäkilä, E. M., Salonen, J., Hirvonen, J. J., Pedrosa, J., Santos, H. A., & Fraga, A. G. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.12.060 · Cited by 16
Prati, F., Zuccotto, F., Fletcher, D., Convery, M. A., Fernandez‐Menendez, R., Bates, R., Encinas, L., Zeng, J., Chung, C., de Dios-Antón, P., et al. (2018) · ChemMedChem · doi:10.1002/cmdc.201700774 · Cited by 22
Jankute, M., Alderwick, L. J., Moorey, A. R., Joe, M., Gurcha, S. S., Eggeling, L., Lowary, T. L., Dell, A., Pang, P., Yang, T., et al. (2018) · The Cell Surface · doi:10.1016/j.tcsw.2018.06.003 · Cited by 16
“As a result, the synthesis of the intricate cell wall matrix provides excellent drug targets for some of the widely used TB drugs, including ethambutol (EMB) and isoniazid (Banerjee et al., 1994; Belanger et al., 1996; Telenti et al., 1997).”
Kumari, M., Tiwari, N., Chandra, S., & Subbarao, N. (2018) · International Journal of Computational Biology and Drug Design · doi:10.1504/ijcbdd.2018.094630 · Cited by 17
Li, Q., Huang, C., Xu, D., Xie, L.-N., Shao, J., Mao, L., Kalyanaraman, B., & Zhu, B. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.07.012 · Cited by 17
Kruh‐Garcia, N. A., Rawat, R., Ruzsicska, B. P., & Tonge, P. J. (2007) · Protein Science · doi:10.1110/ps.062749007 · Cited by 17
“While mutations in inhA correlate with INH resistance, there is also evidence that INH forms a complex with KasA, the FAS-II b-ketoacyl synthase condensing enzyme (Banerjee et al. 1994; Mdluli et al. 1996, 1998; Marrakchi et al. 2000; Slayden et al. 2000; Vilcheze et al. 2000; Larsen et al. 2002; Kremer et al. 2003).”
BackgroundYang, J. K., Yoon, H., Ahn, H. J., Lee, B. I., Cho, S., Waldo, G. S., Park, M., & Suh, S. W. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444901018789 · Cited by 16
KatG as Counterselection Marker for Nontuberculous Mycobacteria
Gagliardi, A., Selchow, P., Luthra, S., Schäfle, D., Schulthess, B., & Sander, P. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02508-19 · Cited by 17
“InhA, an enzyme involved in mycolic acid synthesis (4).”
BackgroundPaterson, R. L., Manna, M. P. L., Souza, V. A. D., Walker, A., Gibbs‐Howe, D., Kulkarni, R., Fergusson, J. R., Mulakkal, N. C., Monteiro, M., Bunjobpol, W., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2318003121 · Cited by 17
“An additional consideration is that isoniazid, a bactericidal agent, is only effective against metabolically active Mtb and may be rendered inactive due to common mutations in katG, inhA or its promoter region (66–68).”
BackgroundDeshpande, A., Likhar, R., Khan, T. A., & Omri, A. (2024) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2400536 · Cited by 16
Rapid molecular screening for multidrug‐resistant tuberculosis in a resource‐limited region of China
Zhang, D., Liu, B., Wang, Y., & Pang, Y. (2014) · Tropical Medicine & International Health · doi:10.1111/tmi.12359 · Cited by 16
“tuberculosis, including katG, inhA, oxyR, ahpC and kasA (Zhang et al. 1992; Banerjee et al. 1994; Lee et al. 1999; Almeida Da Silva & Palomino 2011).”
BackgroundSynthesis and antimycobacterial activity of (+)‐usnic acid conjugates
Cirillo, D. M., Borroni, E., Festoso, I., Monti, D., Romeo, S., Mazier, D., & Verotta, L. (2018) · Archiv der Pharmazie · doi:10.1002/ardp.201800177 · Cited by 16
Identification and validation of the mode of action of the chalcone anti-mycobacterial compounds
Anagani, B., Singh, J., Bassin, J. P., Besra, G. S., Benham, C. D., Reddy, T. R. K., Cox, J. A. G., & Goyal, M. (2020) · The Cell Surface · doi:10.1016/j.tcsw.2020.100041 · Cited by 15
Tonge, P. J. (2000) · Nature Structural Biology · doi:10.1038/72458 · Cited by 22
Iron enhances the susceptibility of pathogenic mycobacteria to isoniazid, an antitubercular drug
Sritharan, M., Yeruva, C. V., Sivasailappan, S. C., & Duggirala, S. (2006) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-006-9183-8 · Cited by 16
“Mutation of inhA can also result in resistance to INH ( Banerjee et al. 1994 ).”
BackgroundTuberculosis in the context of emerging and reemerging diseases
Brennan, P. J. (1997) · FEMS Immunology & Medical Microbiology · doi:10.1016/s0928-8244(97)00056-4 · Cited by 22
Jankute, M., Byng, C. V., Alderwick, L. J., & Besra, G. S. (2014) · Glycoconjugate Journal · doi:10.1007/s10719-014-9549-3 · Cited by 19
“Importantly, a number of anti-TB drugs, such as ethambutol [13–15] and isoniazid [16, 17], target the biosynthesis of the mAGP complex.”
BackgroundProzorov, A. A., Зайчикова, М. В., & Даниленко, В. Н. (2012) · Russian Journal of Genetics · doi:10.1134/s1022795411120118 · Cited by 16
“However, isoniazid resistant strains with mutations of the inhA gene (see above) are resistant to ethionamide as well [82].”
BackgroundGenotypic characterization of drug resistant Mycobacterium tuberculosis in Quebec, 2002-2012
Spinato, J., Boivin, É., Bélanger-Trudelle, É., Fauchon, H., Tremblay, C. L., & Soualhine, H. (2016) · BMC Microbiology · doi:10.1186/s12866-016-0786-4 · Cited by 15
Tuberculosis: Is the landscape changing?
Khatua, S., Geltemeyer, A. M., & Gourishankar, A. (2016) · Pediatric Research · doi:10.1038/pr.2016.205 · Cited by 18
Prieri, M., Frita, R., Probst, N., Sournia‐Saquet, A., Bourotte, M., Deprez, B. P., Baulard, A. R., & Willand, N. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.09.038 · Cited by 15
Identification of Mutations Conferring Tryptanthrin Resistance to Mycobacterium smegmatis
Frolova, S. G., Klimina, K. M., Kumar, R., Vatlin, A. A., Salunke, D. B., Kendrekar, P. S., Даниленко, В. Н., & Maslov, D. A. (2020) · Antibiotics · doi:10.3390/antibiotics10010006 · Cited by 15
“tuberculosis enoyl-acyl carrier protein reductase (InhA) [19]—an enzyme playing a key role in the biosynthesis of mycolic acids, a primary target of isoniazid [20].”
BackgroundEiglmeier, K., Fsihi, H., Heym, B., & Cole, S. T. (1997) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1997.tb10340.x · Cited by 15
Enomoto, Y., Sugita, M., Matsunaga, I., Naka, T., Sato, A., Kawashima, T., Shimizu, K., Takahashi, H., Norose, Y., & Yano, I. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.070 · Cited by 15
Diagnóstico rápido de la tuberculosis. Detección de mecanismos de resistencia
Viñuelas‐Bayón, J., Vitoria, M. A., & Samper, S. (2017) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2017.01.015 · Cited by 17
“Los autores declaran no tener ningún conflicto de intereses.”
Molecular Mapping of Lipoarabinomannans on Mycobacteria
Verbelen, C., Christiaens, N., Alsteens, D., Duprès, V., Baulard, A. R., & Dufrêne, Y. F. (2009) · Langmuir · doi:10.1021/la900302a · Cited by 15
New drug susceptibility test for Mycobacterium tuberculosis using the hybridization protection assay
Miyamoto, J., Koga, H., KOHNO, S., Tashiro, T., & Hara, K. (1996) · Journal of Clinical Microbiology · doi:10.1128/jcm.34.5.1323-1326.1996 · Cited by 15
“Furthermore, the genetic characteristics of drug resistance of mycobacteria have been identified, and the presence of specific genes related to resistance to a few drugs has already been confirmed (2, 19, 23).”
BackgroundZhang, Q., Han, J., Zhu, Y., Tan, S., & Liu, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710102 · Cited by 14
In Vitro and In Vivo Efficacy of NITD-916 against Mycobacterium fortuitum
Roquet, F., Alcaraz, M., Hamela, C., Abendroth, J. A., Edwards, T. E., & Kremer, L. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01607-22 · Cited by 15
“In addition, the mycolic acid biosynthetic pathway represents a validated site of action for the firstintent drug INH and the second-intent drug ethionamide (ETH) (20).”
BackgroundInfluentialFil, M., & Alibert, S. (2024) · BioMed · doi:10.3390/biomed4030018 · Cited by 14
Allegui, Z., Ghariani, A., Draoui, H., Ghezal, A., Mehiri, E., & Slim-Saidi, L. (2012) · International Journal of Mycobacteriology · doi:10.1016/j.ijmyco.2012.01.006 · Cited by 14
da Costa, A. L. P., Pauli, I., Dorn, M., SCHROEDER, E., Zhan, C., & de Souza, O. N. (2011) · Journal of Molecular Modeling · doi:10.1007/s00894-011-1200-7 · Cited by 14
“for long-chain substrates (12–24 carbons) [7], consistent with its involvement in mycolic acid biosynthesis [8].”
BackgroundMethodUnissa, A. N., Sukumar, S., & Hanna, L. E. (2017) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2017.80.3.255 · Cited by 14
Raghunandanan, S., Jose, L., & Kumar, R. A. (2018) · The Journal of Antibiotics · doi:10.1038/s41429-018-0098-z · Cited by 15
Potentials of Diphenyl Ether Scaffold as a Therapeutic Agent: A Review
Kini, S. G., Rathi, E., Kumar, A., & Bhat, V. G. (2019) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557519666190312150132 · Cited by 14
Mycobacterial Epoxide Hydrolase EphD Is Inhibited by Urea and Thiourea Derivatives
Madacki, J., Kopál, M., Jackson, M., & Korduláková, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062884 · Cited by 16
“The mycobacterial cell envelope is an important target for antimycobacterial compounds, with the most notable examples being first-line antituberculotics INH, which inhibits the FASII enoyl-ACP reductase InhA [19,20], and EMB, which interferes with the synthesis of arabinogalactan [21].”
BackgroundCao, B., Mijiti, X., Deng, L., Wang, Q., Yu, J.-J., Anwaierjiang, A., Qian, C., Li, M., Fang, D., Jiang, Y., et al. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s407525 · Cited by 14
“One of the two INHRETHR isolates had the ethA (I34T) mutation to account for ETH resistance, but no other mutation to explain its resistance to INH, and another strain contained mutations both in katG and ahpC associated with INH resistance but no other mutation to explain its resistance to ETH.”
BackgroundInfluentialGausi, K., Ignatius, E. H., Jager, V. R. D., Upton, C. M., Kim, S., McKhann, A., Moran, L. E., Wiesner, L., von Groote-Bidlingmaier, F., Marzinek, P., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202311-2004oc · Cited by 14
Malhotra, P., & Farber, B. F. (2011) · PubMed · Cited by 14
Is the isonicotinoyl radical generated during activation of isoniazid by MnIII-pyrophosphate?
Nguyen, M., Claparols, C., Bernadou, J., & Meunier, B. (2002) · Comptes Rendus Chimie · doi:10.1016/s1631-0748(02)01370-x · Cited by 15
Crystal Structure and Comparative Functional Analyses of a Mycobacterium Aldo-Keto Reductase
Scoble, J. A., McAlister, A. D., Fulton, Z., Troy, S., Byres, E., Vivian, J. P., Brammananth, R., Wilce, M. C. J., Nours, J. L., Zaker-Tabrizi, L., et al. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.02.021 · Cited by 16
Shaw, D. J., Robb, K., Vetter, B. V., Tong, M., Molle, V., Hunt, N. T., & Hoskisson, P. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-05042-4 · Cited by 14
Rotta, M., Timmers, L. F. S. M., Sequeiros-Borja, C. E., Bizarro, C. V., de Souza, O. N., Santos, D. S., & Basso, L. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-07266-w · Cited by 16
Nyinoh, I. W., & McFadden, J. (2018) · Drug Development Research · doi:10.1002/ddr.21497 · Cited by 14
A highly efficient Baby Spinach-based minimal modified sensor (BSMS) for nucleic acid analysis
Soni, R., Sharma, D., Krishna, A. M., Sathiri, J., & Sharma, A. K. (2019) · Organic & Biomolecular Chemistry · doi:10.1039/c9ob01414d · Cited by 14
Kumar, V., & Sobhia, M. E. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.27 · Cited by 15
Hazari, P. P., Chuttani, K., Kumar, N., Mathur, R., Sharma, R., Singh, B., & Mishra, A. K. (2009) · The Open Nuclear Medicine Journal · doi:10.2174/1876388x00901010033 · Cited by 14
“Isoniazid (isonicotinic acid hydrazide (INH) has been utilized as frontline agent in drug composition to treat Mycobacterium tuberculosis [1-3].”
BackgroundDutt, A. K., & Stead, W. W. (1997) · Disease-a-Month · doi:10.1016/s0011-5029(97)90023-7 · Cited by 14
Powers, L. S., Hillar, A., & Loewen, P. C. (2001) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(00)00221-1 · Cited by 14
Extra and intracellular expression of Mycobacterium tuberculosis genes
Smith, I., Dussurget, O., Rodríguez, G. M., Timm, J., Gomez, M., Dubnau, J., Gold, B., & Manganelli, R. (1998) · Tubercle and Lung Disease · doi:10.1054/tuld.1998.0010 · Cited by 14
Radhakrishnan, S. K., & Sundaramurthy, V. (2026) · mBio · doi:10.1128/mbio.03959-25 · Cited by 14
Anand, P. K., Kumar, A., Saini, A., & Kaur, J. (2022) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2022.107677 · Cited by 13
Maitre, T., Baulard, A. R., Aubry, A., & Véziris, N. (2023) · Infectious Diseases Now · doi:10.1016/j.idnow.2023.104807 · Cited by 13
Punkvang, A., Saparpakorn, P., Hannongbua, S., Wolschann, P., Berner, H., & Pungpo, P. (2010) · Monatshefte für Chemie - Chemical Monthly · doi:10.1007/s00706-010-0359-4 · Cited by 13
Chakraborty, N., De, C., Bhattacharyya, S., Mukherjee, A., Santra, S., Banerjee, D., Sarkar, R. N., & Guha, S. K. (2009) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/j.trstmh.2009.09.004 · Cited by 13
Kronenberger, T., Fernandes, P. O., Franco, I. D., Poso, A., & Maltarollo, V. G. (2019) · ChemMedChem · doi:10.1002/cmdc.201900415 · Cited by 13
Mathuria, J. P., Nath, G., Samaria, J. K., & Anupurba, S. (2009) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2009.09.008 · Cited by 16
Dantes, R., Metcalfe, J. Z., Kim, E., Kato‐Maeda, M., Hopewell, P. C., Kawamura, M., Nahid, P., & Cattamanchi, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037956 · Cited by 16
“Resistance to INH in Mycobacterium tuberculosis is mediated by at least two genes, katG [3] and inhA [4].”
BackgroundDesigning and testing single tablet for tuberculosis treatment through electrospinning
Hassounah, I., Shehata, N., Kimsawatde, G. C., Hudson, A. G., Sriranganathan, N., Joseph, E. G., & Mahajan, R. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-41533-0.00011-8 · Cited by 17
Tangarife, V. G., Restrepo, A. J. G., Robledo, J., & Hernández-Sarmiento, J. M. (2018) · Revista de Salud Pública · doi:10.15446/rsap.v20n4.50575 · Cited by 28
Andrade, C. H., Pasqualoto, K. F. M., Zaim, M. H., & Ferreira, E. I. (2008) · Revista Brasileira De Ciencias Farmaceuticas · doi:10.1590/s1516-93322008000200002 · Cited by 14
Intracellular location of catalase-peroxidase hydroperoxidase I of Escherichia coli
Hillar, A., Caeseele, L. V., & Loewen, P. C. (1999) · FEMS Microbiology Letters · doi:10.1016/s0378-1097(98)00558-8 · Cited by 13
The molecular mechanisms of drug resistance in Mycobacterium tuberculosis
Takiff, H. E. (2000) · Resurgent and emerging infectious diseases · doi:10.1007/978-94-011-4084-3_6 · Cited by 16
Labó, M., Gusberti, L., Rossi, E. D., Speziale, P., & Riccardi, G. (1998) · Microbiology · doi:10.1099/00221287-144-3-807 · Cited by 13
“drug is converted inside the bacterium to an activated form by the catalase-peroxidase enzyme, encoded by the katG gene (Zhang et al., 1993), and that the activated drug then inhibits the product of the inhA gene, an enzyme probably involved in mycolic acid biosynthesis (Banerjee et al., 1994).”
BackgroundMethodResultInfluentialSolving the dilemma of antimycobacterial chemotherapy
Rastogi, N., & Falkinham, J. O. (1996) · Research in Microbiology · doi:10.1016/0923-2508(96)80196-3 · Cited by 13
“In a similar fashion, the recent cloning and sequencing of another M. tuberculosis gene responsible for conferring isoniazid resistance (i.e. inhA gene) led to its identification as an enoylacyl-carrier protein reductase (Banerjee et al., 1994; Dessert et al., 1995).”
ResultKawamura, A., Sandy, J., Upton, A. M., Noble, M. E. M., & Sim, E. (2002) · Protein Expression and Purification · doi:10.1016/s1046-5928(02)00592-2 · Cited by 13
Soni, V., Rosenn, E. H., & Venkataraman, R. (2023) · Biochemical Journal · doi:10.1042/bcj20230173 · Cited by 13
Structural insights into terminal arabinosylation of mycobacterial cell wall arabinan
Liu, Y., Brown, C. M., Erramilli, S. K., Su, Y.-C., Guu, S.-Y., Tseng, P., Wang, Y.-J., Duong, N. H., Tokarz, P., Kloss, B., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58196-5 · Cited by 13
Mathew, B., Suresh, J., Mathew, G. E., Sonia, G., & Krishnan, G. K. (2014) · Europe PMC (PubMed Central) · Cited by 12
Integrated analysis of ethionamide resistance loci in Mycobacterium tuberculosis clinical isolates
da Silva, D. A., Ferreira, N. V., Rêgo, A. M., Barbosa, P. C. P., Machado, R. F., Pimentel, A. D. F., dos Reis, L. M., de Pina, L. C., Redner, P., Caldas, P. C. D. S., et al. (2018) · Tuberculosis · doi:10.1016/j.tube.2018.08.010 · Cited by 13
Drug resistant tuberculosis: Current scenario and impending challenges
Dewhare, S. S. (2021) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2021.04.008 · Cited by 13
New ethionamide boosters and EthR2: structural and energetic analysis
Vianna, J. F., Bezerra, K. S., Costa, A. H. L., Barbosa, E. D., Neto, J. X., Oliveira, J. I. N., Freire, V. N., & Fulco, U. L. (2021) · Physical Chemistry Chemical Physics · doi:10.1039/d1cp02853g · Cited by 12
Campen, R., Ackerley, D. F., Cook, G. M., & O’Toole, R. (2015) · Tuberculosis · doi:10.1016/j.tube.2015.03.012 · Cited by 15
“As InhA is the primary target of isoniazid [17], we also examined the effect of inhA overexpression on the activity of the isoniazid analogues.”
BackgroundJaksuwan, R., Tharavichikul, P., Patumanond, J., Chuchottaworn, C., Chanwong, S., Smithtikarn, S., & Settakorn, J. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s130203 · Cited by 12
“20,22 RIF is combined with INH as the main anti-TB drug, and it is inferred with transcription by the DNA-dependent RNA polymerase by binding to the β -subunit hindering transcription organisms related to rpoB 531 mutation, 23–25 which destroys the organisms.”
Kuo, C.-Y., Wang, W., Huang, C., Chen, Y., & Lu, P. (2017) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2017.05.008 · Cited by 12
Vartak, A., Goins, C. M., de Moura, V. C. N., Schreidah, C. M., Landgraf, A. D., Lin, B., Du, J., Jackson, M., Ronning, D. R., & Sucheck, S. J. (2019) · MedChemComm · doi:10.1039/c9md00122k · Cited by 12
DNA microarrays: translational tools for understanding the biology of Mycobacterium tuberculosis
Barry, C. E., & Schroeder, B. G. (2000) · Trends in Microbiology · doi:10.1016/s0966-842x(00)01740-6 · Cited by 12
Coelho, M. B., Costa, E. R. D., Vasconcellos, S. E. G., Linck, N., Ramos, R. M., de Amorim, H. L. N., Suffys, P. N., Santos, A. R., da Silva, P. E. A., Ramos, D. F., et al. (2011) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2011.03.017 · Cited by 14
Punkvang, A., Saparpakorn, P., Hannongbua, S., Wolschann, P., & Pungpo, P. (2010) · Molecules · doi:10.3390/molecules15042791 · Cited by 12
“Isoniazid (INH) has the greatest bactericidal activity and is used almost from the outset of tuberculosis chemotherapy [11–13].”
BackgroundZhang, S.-L., Qi, H., Qiu, D., Li, D., Zhang, J., Du, C., Wang, G., Yang, Z., & Sun, Q. (2007) · Biochemical Genetics · doi:10.1007/s10528-006-9074-6 · Cited by 12
“Mutations in katG are responsible for 60–70% of INH-resistant strains (Ramaswamy and Musser, 1998; Zhang et al., 2000; Herrera et al., 2004), and 20 to 35% of INH-resistant strains contain mutations in the inhA regulatory region (Banerjee et al., 1994).”
BackgroundSarıbaş, Z., Yurdakul, P., Alp, A., & Günalp, A. (2005) · PubMed · Cited by 16
Mechanism of Drug Resistance in Mycobacterium tuberculosis
Pym, A. S., & Cole, S. T. (2007) · CRC Press eBooks · doi:10.1201/9781420008753.ch13 · Cited by 14
Ho, V. Q. T., Verboom, T., Rong, M. K., Habjan, E., Bitter, W., & Speer, A. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01445-20 · Cited by 15
“culosis toward ETH and INH probably relate to the activities and/or expression levels of ethA and katG (23).”
BackgroundBartoš, M., Falkinham, J. O., & Pavlík, I. (2004) · Veterinární Medicína · doi:10.17221/5691-vetmed · Cited by 13
Cui, Y., Lanne, A., Peng, X., Browne, E., Bhatt, A., Coltman, N. J., Craven, P. G. E., Cox, L. R., Cundy, N. J., Dale, K., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01643 · Cited by 11
RETRACTED: Targeting Mycobacterial Enzymes with Natural Products
Sieniawska, E. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.08.012 · Cited by 12
RetractedKey Targets and Relevant Inhibitors for the Drug Discovery of Tuberculosis
Xiong, X., Xu, Z., Yang, Z., Liu, Y., Wang, D., Dong, M., Parker, E. J., & Zhu, W. (2013) · Current Drug Targets · doi:10.2174/1389450111314060009 · Cited by 12
Metadata
- Authors
- Banerjee, A., Dubnau, E., Quemard, A., Balasubramanian, V., Um, K. S., Wilson, T., Collins, D., de Lisle, G., & Jacobs, W. R.
- Affiliations
- Albert Einstein College of Medicine (US)
- Howard Hughes Medical Institute, Albert Einstein College of Medicine, Bronx, NY 10461.
- AgResearch (NZ)
- AgResearch, Wallaceville Animal Research Center, Upper Hutt, New Zealand.
- Venue
- Science
- Published
- 1994-01-14
- Volume
- 263
- Issue
- 5144
- Pages
- 227-230
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2075000963
- Cited by
- 1,389
- References
- 46
- Citations by year
- 2026: 24 · 2025: 32 · 2024: 31 · 2023: 43 · 2022: 49 · 2021: 39 · 2020: 45 · 2019: 52 · 2018: 52 · 2017: 62 · 2016: 45 · 2015: 54 · 2014: 69 · 2013: 39 · 2012: 57
- FWCI
- 46.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5u01ai030189-03)
- National Institute of Allergy and Infectious Diseases (AI 27160, UO1AI30189)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Microbial Natural Products and Biosynthesis
- Keywords
- inhA gene, isoniazid, ethionamide, Mycobacterium tuberculosis, therapeutic target, drug resistance, missense mutations, mycolic acid biosynthesis, Mycobacterium smegmatis, Mycobacterium bovis BCG, antitubercular agents
- MeSH terms
- Amino Acid Sequence, Bacterial Proteins, Base Sequence, Cloning, Molecular, Drug Resistance, Microbial, Ethionamide, Genes, Bacterial, Isoniazid, Molecular Sequence Data, Mutation, Mycobacterium, Mycobacterium bovis, Mycobacterium tuberculosis, Mycolic Acids, Oxidoreductases, Open Reading Frames, Sequence Alignment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.